News & Updates

Adjuvant FOLFIRINOX ups survival in pancreatic cancer

15 Oct 2022 by

Adjuvant chemotherapy with a modified dose of FOLFIRINOX (mFOLFIRINOX) was associated with significantly better survival outcomes, particularly disease-free survival (DFS) and overall survival (OS), compared with single-agent gemcitabine in patients with resected pancreatic ductal adenocarcinoma (PDAC), according to a 5-year analysis of the PRODIGE 24/Canadian Cancer Trials Group PA6* study.

Adjuvant FOLFIRINOX ups survival in pancreatic cancer

15 Oct 2022

Updated BEST results: No major difference between EES or CABG for multivessel disease

14 Oct 2022 by

In patients with multivessel coronary artery disease, the risk of any-cause death, myocardial infarction (MI), or target vessel revascularization (TVR) did not vary according to whether patients underwent percutaneous coronary intervention (PCI) with everolimus-eluting stents (EES) or coronary artery bypass graft (CABG), extended follow-up of the BEST* trial showed.

Updated BEST results: No major difference between EES or CABG for multivessel disease

14 Oct 2022

Dexmedetomidine-related fever seen in some adult ICU patients

14 Oct 2022

A few patients in the intensive care unit (ICU) have registered a fever >38.5 °C while on dexmedetomidine therapy, reports a recent study.

Dexmedetomidine-related fever seen in some adult ICU patients

14 Oct 2022

Fluoroquinolone reduction initiative lowers antibiotic use, resistance

14 Oct 2022

A nonrestrictive fluoroquinolone reduction initiative at an urban teaching hospital has substantially lessened the use of this drug, which is associated with decreased antibiotic resistance in Staphylococcus aureus and Pseudomonas aeruginosa, a study has shown.

Fluoroquinolone reduction initiative lowers antibiotic use, resistance

14 Oct 2022

Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC

14 Oct 2022 by

In the long-term follow-up of the KEYNOTE-604 study, the combination regimen comprising pembrolizumab and etoposide/platinum (EP*) continued to demonstrate survival benefit as first-line therapy for patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC).

Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC

14 Oct 2022

Intravitreal implant attenuates treatment burden in diabetic macular edema

14 Oct 2022

The use of fluocinolone acetonide improves visual outcomes and disease control in patients with diabetic macular edema (DME), as measured by a significant reduction in annual treatment burden, according to a study.

Intravitreal implant attenuates treatment burden in diabetic macular edema

14 Oct 2022

Prexasertib works in select patients with recurrent ovarian cancer

14 Oct 2022

CHK1 inhibition with prexasertib appears to have durable activity in some patients with recurrent ovarian cancer regardless of clinical characteristics, BRCA status, or prior therapies, according to the results of a phase II trial.

Prexasertib works in select patients with recurrent ovarian cancer

14 Oct 2022

Antidepressant med may double as sleep apnoea treatment

13 Oct 2022 by

The antidepressant reboxetine demonstrates therapeutic potential in patients with obstructive sleep apnoea (OSA), with a recent study showing that the drug helps lower disease severity.

Antidepressant med may double as sleep apnoea treatment

13 Oct 2022

Tacrolimus dose reduction needed in renal transplant patients on fluconazole

13 Oct 2022

Renal transplant patients require a 20-percent reduction in tacrolimus (TAC) total daily dose (TDD) when used in tandem with low-dose fluconazole (LDF) to achieve therapeutic levels, suggests a study.

Tacrolimus dose reduction needed in renal transplant patients on fluconazole

13 Oct 2022

Do fluoroquinolones raise risk of hospital admission for suicidality?

13 Oct 2022 by

Use of fluoroquinolones for the treatment of pneumonia or urinary tract infection (UTI) does not appear to markedly increase the risk of hospital admission or emergency department visits due to suicidality compared with azithromycin or combined trimethoprim and sulfamethoxazole, a study has shown.

Do fluoroquinolones raise risk of hospital admission for suicidality?

13 Oct 2022

News & Updates

Filter by Specialty:

Specialty:

Adjuvant FOLFIRINOX ups survival in pancreatic cancer

Adjuvant FOLFIRINOX ups survival in pancreatic cancer

Updated BEST results: No major difference between EES or CABG for multivessel disease

Updated BEST results: No major difference between EES or CABG for multivessel disease

Dexmedetomidine-related fever seen in some adult ICU patients

Dexmedetomidine-related fever seen in some adult ICU patients

Fluoroquinolone reduction initiative lowers antibiotic use, resistance

Fluoroquinolone reduction initiative lowers antibiotic use, resistance

Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC

Pembrolizumab-based regimen continues to show favourable signals for ES-SCLC

Intravitreal implant attenuates treatment burden in diabetic macular edema

Intravitreal implant attenuates treatment burden in diabetic macular edema

Prexasertib works in select patients with recurrent ovarian cancer

Prexasertib works in select patients with recurrent ovarian cancer

Antidepressant med may double as sleep apnoea treatment

Antidepressant med may double as sleep apnoea treatment

Tacrolimus dose reduction needed in renal transplant patients on fluconazole

Tacrolimus dose reduction needed in renal transplant patients on fluconazole

Do fluoroquinolones raise risk of hospital admission for suicidality?

Do fluoroquinolones raise risk of hospital admission for suicidality?